For High-Definition, Click
In the final segment of the discussion, John Marshall, MD, asks the panelists to share their final thoughts on the treatment of metastatic colorectal cancer (mCRC). Johanna Bendell, MD, comments that expanded KRAS
testing should be conducted in patients with mCRC. Also, patients with the BRAF
mutation should be encouraged to enter clinical trials. Bendell further remarks that there are many agents in development; through patient participation in clinical trials, additional knowledge and experience will be gained regarding the treatment of mCRC.
The field is currently in the midst of a molecular revolution, notes Heinz-Josef Lenz, MD, and over time, more will be learned about patient selection for targeted treatments. Lenz adds that substantial progress will be made as advances in molecular biology are matched with appropriate targeted therapies.
There are many treatment options available and the treatment of mCRC is an art, comments Marwan Fakih, MD. It is important to discuss treatment goals with patients before initiating therapy, adds Fakih.
Alan Venook, MD, recommends a multidisciplinary approach, as opinions from other clinicians can be valuable when formulating a treatment plan. Venook further comments that it is important for patients to be offered enrollment in clinical trials, as the results of clinical trials will help address open questions regarding the treatment of mCRC.
Marshall wraps up the segment by commenting that there are many resources available for patients, including websites and advocacy groups, for example. He adds that it is important for clinicians to engage patients in discussions regarding enrollment in clinical trials.